TRV027: Phase IIb started

Trevena began the double-blind Phase IIb BLAST-AHF trial to compare 1, 5 and 25 mg/hour IV TRV027 administered for 48-96 hours plus standard therapy vs. placebo plus standard therapy in about 500 pati...